EP2675471A4 - Compositions liées à la sérumalbumine humaine et procédés d'utilisation - Google Patents

Compositions liées à la sérumalbumine humaine et procédés d'utilisation

Info

Publication number
EP2675471A4
EP2675471A4 EP11858565.2A EP11858565A EP2675471A4 EP 2675471 A4 EP2675471 A4 EP 2675471A4 EP 11858565 A EP11858565 A EP 11858565A EP 2675471 A4 EP2675471 A4 EP 2675471A4
Authority
EP
European Patent Office
Prior art keywords
hsa
methods
related compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11858565.2A
Other languages
German (de)
English (en)
Other versions
EP2675471A1 (fr
Inventor
Changshou Gao
Chaity Chaudhury
Xiaotao Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/024855 external-priority patent/WO2011103076A1/fr
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP2675471A1 publication Critical patent/EP2675471A1/fr
Publication of EP2675471A4 publication Critical patent/EP2675471A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11858565.2A 2011-02-15 2011-08-09 Compositions liées à la sérumalbumine humaine et procédés d'utilisation Withdrawn EP2675471A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2011/024855 WO2011103076A1 (fr) 2010-02-16 2011-02-15 Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation
PCT/US2011/047040 WO2012112188A1 (fr) 2011-02-15 2011-08-09 Compositions liées à la sérumalbumine humaine et procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP2675471A1 EP2675471A1 (fr) 2013-12-25
EP2675471A4 true EP2675471A4 (fr) 2015-01-28

Family

ID=46675795

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11858565.2A Withdrawn EP2675471A4 (fr) 2011-02-15 2011-08-09 Compositions liées à la sérumalbumine humaine et procédés d'utilisation

Country Status (7)

Country Link
EP (1) EP2675471A4 (fr)
JP (1) JP2014510518A (fr)
KR (1) KR20140012094A (fr)
CN (1) CN103379915A (fr)
AU (1) AU2011359378A1 (fr)
CA (1) CA2826683A1 (fr)
WO (1) WO2012112188A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092135A2 (fr) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Variants de l'albumine et leurs conjugués
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
JP2013519392A (ja) 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CA2838246C (fr) 2011-06-13 2018-07-10 Csl Limited Anticorps contre g-csfr et leurs utilisations
HK1200842A1 (en) * 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
WO2014072481A1 (fr) * 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Variants d'albumine
WO2014125082A1 (fr) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Modèle pharmacocinétique animal
EP2970406B1 (fr) * 2013-03-15 2017-12-13 Affibody AB Fcrn binding polypeptide
CA2913387C (fr) * 2013-06-12 2024-05-21 Pharis Biotec Gmbh Peptides ayant des activites d'antagoniste contre cxcr4 naturel
WO2015036579A1 (fr) * 2013-09-13 2015-03-19 Novozymes Biopharma Dk A/S Variants d'albumine
JP6306700B2 (ja) * 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
CN107428817B (zh) 2015-03-12 2022-07-12 免疫医疗有限责任公司 纯化白蛋白融合蛋白的方法
WO2017029407A1 (fr) 2015-08-20 2017-02-23 Albumedix A/S Variants de l'albumine et leurs conjugués
ES2781207T3 (es) * 2015-09-23 2020-08-31 Bristol Myers Squibb Co Dominios de fibronectina de tipo iii de unión a seroalbúmina con velocidad de disociación rápida
WO2017112847A1 (fr) 2015-12-22 2017-06-29 Albumedix A/S Souches améliorées pour l'expression de protéines
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
JP2020500306A (ja) 2016-11-04 2020-01-09 オーフス ウニベルシテット 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療
DK3642343T3 (en) 2017-06-20 2022-03-14 Albumedix Ltd Improved protein expression strains
JP7465210B2 (ja) 2017-11-29 2024-04-10 シーエスエル リミティド 虚血－再灌流障害の治療又は予防方法
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
AU2019268410B2 (en) 2018-05-16 2025-01-02 Csl Limited Soluble complement receptor type 1 variants and uses thereof
JP2022509372A (ja) 2018-10-29 2022-01-20 バイオジェン・エムエイ・インコーポレイテッド 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント
CN119285791A (zh) 2019-09-06 2025-01-10 诺华股份有限公司 治疗性融合蛋白
WO2021111143A1 (fr) 2019-12-04 2021-06-10 Albumedix Limited Procédés et compositions produites par ceux-ci
CN115768475A (zh) 2020-06-04 2023-03-07 Csl创新私人有限公司 治疗或预防急性呼吸窘迫综合征的方法
CN114478800B (zh) * 2021-02-05 2022-10-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
EP4608448A1 (fr) 2022-10-28 2025-09-03 Aarhus Universitet Albumine conjuguée à des oligodésoxynucléotides cpg en tant que super composés adjuvants de la réponse immunitaire
EP4442251A1 (fr) 2023-04-05 2024-10-09 Albumedix Ltd Formulations et leurs utilisations
AU2024290964A1 (en) 2023-07-05 2026-01-08 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025158071A1 (fr) 2024-01-26 2025-07-31 Sartorius Albumedix Limited Préparations rétrovirales contenant de l'albumine pour améliorer l'efficacité de transduction, leurs utilisations pour la transduction cellulaire
EP4703468A1 (fr) 2024-08-29 2026-03-04 Sartorius Albumedix Limited Procédés et utilisations
WO2026074121A1 (fr) 2024-10-02 2026-04-09 Sartorius Albumedix Limited Formulations d'albumine et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103076A1 (fr) * 2010-02-16 2011-08-25 Medlmmune, Llc Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404270D0 (en) * 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
BRPI0911652A2 (pt) * 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
AU2010234459A1 (en) * 2009-04-08 2011-11-03 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103076A1 (fr) * 2010-02-16 2011-08-25 Medlmmune, Llc Compositions relatives a l'albumine serique humaine et leurs methodes d'utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012112188A1 *

Also Published As

Publication number Publication date
EP2675471A1 (fr) 2013-12-25
WO2012112188A1 (fr) 2012-08-23
CN103379915A (zh) 2013-10-30
CA2826683A1 (fr) 2012-08-23
JP2014510518A (ja) 2014-05-01
KR20140012094A (ko) 2014-01-29
AU2011359378A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
PH12013501427A1 (en) Melanin modification compositions and methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2678018A4 (fr) Combinaison d'inhibiteurs des kinases et utilisations associées
IL232977B (en) Intra-episode dexmedetomidine preparations and methods of using them
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
GB201411462D0 (en) Prebiotic formulations and methods of use
SG11201501499SA (en) Multi-functional compositions and methods of use
EP2771030A4 (fr) Compositions et méthodes de traitement de protéinopathies
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
PT3366143T (pt) Composições e métodos probióticos
SG11201400668SA (en) Wnt compositions and therapeutic uses of such compositions
SG11201400567QA (en) Cd40l-specific tn3-derived scaffolds and methods of use thereof
SG11201501381PA (en) Topical compositions and methods of use
IL239631A0 (en) Anti-integrin cell 1 antibody preparations and methods of using them
IL235968A0 (en) Polysaccharide preparations and methods of use
EP2709999A4 (fr) Composés de quinazoline-7-éther et méthodes d'utilisation
LT2827883T (lt) Tfpi inhibitoriai ir jų panaudojimo būdai
EP2668044A4 (fr) Compositions et leur utilisation
ZA201308892B (en) Compositions and methods
IL239623A0 (en) Methods and preparations for administering oxybutynin
PL2736328T3 (pl) Biocydowe kompozycje oraz sposoby stosowania
PL2736339T3 (pl) Biocydowe kompozycje oraz sposoby stosowania
GB201116340D0 (en) Compositions and methods
AU2012901658A0 (en) Compositions and methods of use
HK1191056A (en) Compositions and methods of use for determination of he4a

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192466

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20150108

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/765 20060101ALI20141222BHEP

Ipc: A61K 47/48 20060101ALI20141222BHEP

Ipc: A61K 38/38 20060101AFI20141222BHEP

17Q First examination report despatched

Effective date: 20150907

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160318

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1192466

Country of ref document: HK